Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
about
Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.Blood disorders typically associated with renal transplantationPopulation pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients.Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience.Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.Thrombocytopenia after liver transplantation: Should we care?High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantationDrug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q33408239-C9F21FF3-1B78-4BC8-BBF0-C330453E966DQ33421793-5B78A8E5-C58A-429F-BCC1-210760D9DC0CQ34065300-D28231D7-A3A9-45DE-9033-55528A40A836Q34432814-8E20E3B5-DD4C-45C6-9893-BB04C8B8509FQ36868806-C06834E0-9329-4BD0-A307-0D41127BD741Q36929597-957A1227-9D0E-4E80-8194-B53C333451C3Q40537018-09B4CCFD-8356-452F-B7E7-40106FCE0095Q40956620-ECDEAC0C-7ADF-49B1-A0CB-8E27EE52F7A4Q41496012-EB0E63AB-3B98-4536-9087-DA2CFDC69BD9Q54239049-35A900A5-3178-4872-BB0F-2254D88F2151Q56963171-6A9D8B36-756C-4BFA-9FFF-B2FF6FFC81AFQ58805821-DF8D8666-3252-47B1-9474-655B7061C56C
P2860
Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@ast
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@en
type
label
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@ast
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@en
prefLabel
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@ast
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@en
P2093
P2860
P1433
P1476
Efficacy and safety of low-dos ...... enter, retrospective analysis.
@en
P2093
Anil K Chandraker
Colm C Magee
Jennifer L Cina
John A Powelson
Steven A Baroletti
P2860
P304
P356
10.1592/PHCO.24.14.1323.43152
P407
P577
2004-10-01T00:00:00Z